



EXTRAORDINARY INFORMATION

on the resolutions of the Sole Shareholder

ARTS ET TECHNIQUES DU PROGRÈS (duly organised and existing under the laws of France, and having an office and principal place of business at 25 rue Eugène Vignat, 45000 Orléans FRANCE, Registration No.: 582 057 600) as the sole shareholder (hereinafter referred to as "Sole Shareholder") of Egis Pharmaceuticals Plc (a company duly organized and existing under the laws of Hungary, registration no. 01-10-041762, having its registered office at 30-38 Keresztúri út, H-1106 Budapest, HUNGARY) adopted the following

resolutions

in accordance with paragraph 5 of Section 19, paragraph 2 of Section 284 of the Hungarian Business Associations Act (Act IV of 2006) and Article 16 of the Articles of Association:

Sole Shareholder resolution No. 1/2014.

The Sole Shareholder accepts the consolidated report on the business activity of the Egis Group prepared by the Board of Directors on the year ended 30 September 2013 in accordance with International Financial Reporting Standards (IFRS), and approves the consolidated balance sheet of Egis Pharmaceuticals PLC with assets vs. liabilities and shareholders' equity of HUF 227,117 million, and with consolidated net profit of HUF 20,412 million.

The Sole Shareholder furthermore approves the relevant reports of the Supervisory Board, the Auditor and the Audit Committee.

Sole Shareholder resolution No. 2/2014.

The Sole Shareholder accepts the report on the business activity of Egis Pharmaceuticals PLC (Company) prepared by the Board of Directors on the year ended 30 September 2013 in accordance with the Hungarian Accounting Law, and approves the balance sheet of the Company with assets vs. equity and liabilities of HUF 228,061 million, profit after tax of HUF 20,696 million, and, at the same time, issues the end-of-period clearance to executive officers concerning their indemnification responsibility as specified in 16. f) subsection of the Articles of Association.

The Sole Shareholder furthermore approves the relevant reports of the Supervisory Board, of the Auditor and of the Audit Committee.

Sole Shareholder resolution No. 3/2014.

The Sole Shareholder decides that Egis Pharmaceuticals PLC will pay gross dividend of HUF 2,024.3 million, the equivalent of HUF 260 dividend per share, from the 2012/2013 after-tax profit.

Sole Shareholder resolution No. 4/2014.

The Sole Shareholder resolves to increase the officials' remuneration for 2013/2014 in accordance with the general salary increase applied by Egis Pharmaceuticals PLC in Hungary to its own employees for the year 2014.

The Sole Shareholder adopted the above resolutions on the place and date below and sends them to the Board of Directors.

Sole Shareholder resolution No. 5/2014.

The Sole Shareholder appoints Ernst & Young Könyvvizsgáló Kft. (1132 Budapest, Váci út 20., Reg. No. MKVK 001165) as auditor of the Company according to the following details:

- the natural person appointed within the auditing company is Ms BERTALAN Zsuzsanna (Reg. No. MKVK 005611); in case of any prevention, Mr BARABÁS Csaba (Reg. No. MKVK 005787) will act as her deputy;
- the mandate is valid for the period up to the date of the Sole Shareholder resolution closing the financial year lasting from October 1, 2013 till September 30, 2014;
- the appointed auditing company performs its activity on the basis of the contract concluded with the Company; and the contracted fee of the appointed auditing company will be HUF 21.6 million.

Budapest, January 31, 2014

Egis Pharmaceuticals PLC

